Statement of Financial Position, Liabilities and Stockholders' Equity
Difficulty: Beginner
The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.
Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.
Eli Lilly & Co., Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity
USD $ in thousands
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Short-term borrowings and current maturities of long-term debt | 3,706,600 | 1,937,400 | 6,100 | 2,688,700 | 1,012,600 | ||||||
| Accounts payable | 1,410,700 | 1,349,300 | 1,338,200 | 1,128,100 | 1,119,300 | ||||||
| Employee compensation | 997,900 | 896,900 | 967,000 | 759,000 | 943,900 | ||||||
| Sales rebates and discounts | 4,465,100 | 3,914,900 | 2,560,100 | 2,068,800 | 1,941,700 | ||||||
| Dividends payable | 590,600 | 548,100 | 539,000 | 530,300 | 523,500 | ||||||
| Income taxes payable | 532,900 | 119,100 | 358,900 | 93,500 | 254,400 | ||||||
| Deferred income taxes | – | – | – | 1,466,500 | 792,800 | ||||||
| Other current liabilities | 2,832,100 | 2,220,900 | 2,460,300 | 2,472,600 | 2,328,400 | ||||||
| Current liabilities | 14,535,900 | 10,986,600 | 8,229,600 | 11,207,500 | 8,916,600 | ||||||
| Long-term debt, excluding current maturities | 9,940,500 | 8,367,800 | 7,972,400 | 5,367,700 | 4,200,300 | ||||||
| Accrued retirement benefits | 3,513,900 | 2,453,900 | 2,160,300 | 2,562,900 | 1,549,400 | ||||||
| Long-term income taxes payable | 3,776,500 | 688,900 | 868,900 | 998,500 | 1,078,700 | ||||||
| Other noncurrent liabilities | 1,546,300 | 2,228,200 | 1,747,400 | 1,653,500 | 1,863,000 | ||||||
| Other liabilities | 18,777,200 | 13,738,800 | 12,749,000 | 10,582,600 | 8,691,400 | ||||||
| Total liabilities | 33,313,100 | 24,725,400 | 20,978,600 | 21,790,100 | 17,608,000 | ||||||
| Common stock, no par value | 687,900 | 688,500 | 691,300 | 694,600 | 698,500 | ||||||
| Additional paid-in capital | 5,817,800 | 5,640,600 | 5,552,100 | 5,292,300 | 5,050,000 | ||||||
| Retained earnings | 13,894,100 | 16,046,300 | 16,011,800 | 16,482,700 | 16,992,400 | ||||||
| Employee benefit trust | (3,013,200) | (3,013,200) | (3,013,200) | (3,013,200) | (3,013,200) | ||||||
| Accumulated other comprehensive loss | (5,718,600) | (5,274,000) | (4,580,700) | (3,991,800) | (2,002,700) | ||||||
| Cost of common stock in treasury | (75,800) | (80,500) | (90,000) | (91,400) | (93,600) | ||||||
| Total Eli Lilly and Company shareholders' equity | 11,592,200 | 14,007,700 | 14,571,300 | 15,373,200 | 17,631,400 | ||||||
| Noncontrolling interests | 75,700 | 72,800 | 19,000 | 14,900 | 9,300 | ||||||
| Total equity | 11,667,900 | 14,080,500 | 14,590,300 | 15,388,100 | 17,640,700 | ||||||
| Total liabilities and equity | 44,981,000 | 38,805,900 | 35,568,900 | 37,178,200 | 35,248,700 |
Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).
| Item | Description | The company |
|---|---|---|
| Current liabilities | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. | Eli Lilly & Co.'s current liabilities increased from 2015 to 2016 and from 2016 to 2017. |
| Other liabilities | Amount of obligation due after one year or beyond the normal operating cycle, if longer. | Eli Lilly & Co.'s other liabilities increased from 2015 to 2016 and from 2016 to 2017. |
| Total liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | Eli Lilly & Co.'s total liabilities increased from 2015 to 2016 and from 2016 to 2017. |
| Total Eli Lilly and Company shareholders' equity | Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. | Eli Lilly & Co.'s total Eli Lilly and Company shareholders' equity declined from 2015 to 2016 and from 2016 to 2017. |